Trial Profile
Efficacy of Ranibizumab and Conbercept in Coats' Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Jul 2018
Price :
$35
*
At a glance
- Drugs Conbercept (Primary) ; Ranibizumab (Primary)
- Indications Retinal telangiectasis
- Focus Therapeutic Use
- 31 Jul 2018 New trial record
- 01 Jul 2018 Results published in the Graefes Archive for Clinical and Experimental Ophthalmology.